# Arteris, Inc.: financial statements, quarterly

AIP · Nasdaq · CIK 1667011 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aip.md) · [Financials](/companies/aip/financials.md) · [Filings](/companies/aip/filings.md) · [Insiders](/companies/aip/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aip/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.3](/filings/0001667011-24-000036.md) | [12.5 d](/filings/0001667011-25-000010.md) | [12.9](/filings/0001667011-25-000022.md) | [14.6](/filings/0001667011-25-000029.md) | [14.7](/filings/0001628280-25-048977.md) | [15.5 d](/filings/0001628280-26-007726.md) | [16.5](/filings/0001628280-26-034186.md) | [16.5](/filings/0001628280-26-054464.md) | [17.4](/filings/0001628280-25-048977.md) | [20.1 d](/filings/0001628280-26-007726.md) | [22.9](/filings/0001628280-26-034186.md) | [24.1](/filings/0001628280-26-054464.md) |
| Cost of revenue | $m | [1.3](/filings/0001667011-24-000036.md) | [1.4 d](/filings/0001667011-25-000010.md) | [1.5](/filings/0001667011-25-000022.md) | [1.5](/filings/0001667011-25-000029.md) | [1.5](/filings/0001628280-25-048977.md) | [1.6 d](/filings/0001628280-26-007726.md) | [1.5](/filings/0001628280-26-034186.md) | [1.7](/filings/0001628280-26-054464.md) | [1.8](/filings/0001628280-25-048977.md) | [1.9 d](/filings/0001628280-26-007726.md) | [3.3](/filings/0001628280-26-034186.md) | [3.6](/filings/0001628280-26-054464.md) |
| Gross profit | $m | [12.0](/filings/0001667011-24-000036.md) | [11.1 d](/filings/0001667011-25-000010.md) | [11.5](/filings/0001667011-25-000022.md) | [13.1](/filings/0001667011-25-000029.md) | [13.3](/filings/0001628280-25-048977.md) | [13.9 d](/filings/0001628280-26-007726.md) | [15.0](/filings/0001628280-26-034186.md) | [14.8](/filings/0001628280-26-054464.md) | [15.6](/filings/0001628280-25-048977.md) | [18.3 d](/filings/0001628280-26-007726.md) | [19.7](/filings/0001628280-26-034186.md) | [20.5](/filings/0001628280-26-054464.md) |
| Research and development | $m | [11.0](/filings/0001667011-24-000036.md) | [10.7 d](/filings/0001667011-25-000010.md) | [10.8](/filings/0001667011-25-000022.md) | [10.7](/filings/0001667011-25-000029.md) | [11.9](/filings/0001628280-25-048977.md) | [11.5 d](/filings/0001628280-26-007726.md) | [11.9](/filings/0001628280-26-034186.md) | [12.2](/filings/0001628280-26-054464.md) | [12.6](/filings/0001628280-25-048977.md) | [13.2 d](/filings/0001628280-26-007726.md) | [14.5](/filings/0001628280-26-034186.md) | [16.8](/filings/0001628280-26-054464.md) |
| Operating income | $m | [(8.5)](/filings/0001667011-24-000036.md) | [(9.2) d](/filings/0001667011-25-000010.md) | [(9.1)](/filings/0001667011-25-000022.md) | [(7.4)](/filings/0001667011-25-000029.md) | [(7.9)](/filings/0001628280-25-048977.md) | [(7.1) d](/filings/0001628280-26-007726.md) | [(7.7)](/filings/0001628280-26-034186.md) | [(8.2)](/filings/0001628280-26-054464.md) | [(8.7)](/filings/0001628280-25-048977.md) | [(8.5) d](/filings/0001628280-26-007726.md) | [(9.3)](/filings/0001628280-26-034186.md) | [(13.9)](/filings/0001628280-26-054464.md) |
| Interest expense | $m | [0.1](/filings/0001667011-23-000030.md) | [0.1 d](/filings/0001667011-24-000010.md) | [0.1](/filings/0001667011-24-000016.md) | [0.1](/filings/0001667011-25-000029.md) | [0.1](/filings/0001628280-25-048977.md) | [0.0 d](/filings/0001628280-26-007726.md) | [0.0](/filings/0001628280-26-034186.md) | [0.0](/filings/0001628280-26-054464.md) | [0.0](/filings/0001628280-25-048977.md) | [0.1 d](/filings/0001628280-26-007726.md) | [0.0](/filings/0001628280-26-034186.md) | [0.0](/filings/0001628280-26-054464.md) |
| Income tax | $m | [(0.4)](/filings/0001667011-24-000036.md) | [1.2 d](/filings/0001667011-25-000010.md) | [0.4](/filings/0001667011-25-000022.md) | [1.0](/filings/0001667011-25-000029.md) | [(0.1)](/filings/0001628280-25-048977.md) | [1.2 d](/filings/0001628280-26-007726.md) | [0.3](/filings/0001628280-26-034186.md) | [0.8](/filings/0001628280-26-054464.md) | [0.4](/filings/0001628280-25-048977.md) | [(0.0) d](/filings/0001628280-26-007726.md) | [(3.7)](/filings/0001628280-26-034186.md) | [0.7](/filings/0001628280-26-054464.md) |
| Net income | $m | [(8.2)](/filings/0001667011-24-000036.md) | [(10.5) d](/filings/0001667011-25-000010.md) | [(9.4)](/filings/0001667011-25-000022.md) | [(8.3)](/filings/0001667011-25-000029.md) | [(7.7)](/filings/0001628280-25-048977.md) | [(8.2) d](/filings/0001628280-26-007726.md) | [(8.1)](/filings/0001628280-26-034186.md) | [(9.1)](/filings/0001628280-26-054464.md) | [(9.0)](/filings/0001628280-25-048977.md) | [(8.5) d](/filings/0001628280-26-007726.md) | [(8.0)](/filings/0001628280-26-034186.md) | [(14.1)](/filings/0001628280-26-054464.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0001667011-24-000036.md) | not reported | [(0.25)](/filings/0001667011-25-000022.md) | [(0.22)](/filings/0001667011-25-000029.md) | [(0.20)](/filings/0001628280-25-048977.md) | not reported | [(0.20)](/filings/0001628280-26-034186.md) | [(0.22)](/filings/0001628280-26-054464.md) | [(0.21)](/filings/0001628280-25-048977.md) | not reported | [(0.17)](/filings/0001628280-26-034186.md) | [(0.30)](/filings/0001628280-26-054464.md) |
| Basic EPS | $ per share | [(0.23)](/filings/0001667011-24-000036.md) | not reported | [(0.25)](/filings/0001667011-25-000022.md) | [(0.22)](/filings/0001667011-25-000029.md) | [(0.20)](/filings/0001628280-25-048977.md) | not reported | [(0.20)](/filings/0001628280-26-034186.md) | [(0.22)](/filings/0001628280-26-054464.md) | [(0.21)](/filings/0001628280-25-048977.md) | not reported | [(0.17)](/filings/0001628280-26-034186.md) | [(0.30)](/filings/0001628280-26-054464.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.6](/filings/0001667011-24-000036.md) | [13.7](/filings/0001667011-25-000010.md) | [26.1](/filings/0001667011-25-000022.md) | [22.1](/filings/0001667011-25-000029.md) | [17.8](/filings/0001628280-25-048977.md) | [13.7](/filings/0001628280-26-007726.md) | [16.4](/filings/0001628280-26-034186.md) | [16.1](/filings/0001628280-26-054464.md) | [17.4](/filings/0001628280-25-048977.md) | [33.9](/filings/0001628280-26-054464.md) | [11.7](/filings/0001628280-26-034186.md) | [93.3](/filings/0001628280-26-054464.md) |
| Current assets | $m | [62.0](/filings/0001667011-23-000030.md) | [58.4](/filings/0001667011-25-000010.md) | [61.8](/filings/0001667011-24-000016.md) | [58.9](/filings/0001667011-24-000026.md) | [62.8](/filings/0001667011-24-000036.md) | [69.1](/filings/0001628280-26-007726.md) | [57.4](/filings/0001667011-25-000022.md) | [61.5](/filings/0001667011-25-000029.md) | [61.0](/filings/0001628280-25-048977.md) | [82.4](/filings/0001628280-26-054464.md) | [61.5](/filings/0001628280-26-034186.md) | [146](/filings/0001628280-26-054464.md) |
| Total assets | $m | [102](/filings/0001667011-23-000030.md) | [103](/filings/0001667011-25-000010.md) | [101](/filings/0001667011-24-000016.md) | [96.4](/filings/0001667011-24-000026.md) | [97.7](/filings/0001667011-24-000036.md) | [106](/filings/0001628280-26-007726.md) | [98.3](/filings/0001667011-25-000022.md) | [107](/filings/0001667011-25-000029.md) | [108](/filings/0001628280-25-048977.md) | [115](/filings/0001628280-26-054464.md) | [140](/filings/0001628280-26-034186.md) | [225](/filings/0001628280-26-054464.md) |
| Current liabilities | $m | [44.5](/filings/0001667011-23-000030.md) | [46.4](/filings/0001667011-25-000010.md) | [49.8](/filings/0001667011-24-000016.md) | [51.7](/filings/0001667011-24-000026.md) | [54.2](/filings/0001667011-24-000036.md) | [59.3](/filings/0001628280-26-007726.md) | [56.5](/filings/0001667011-25-000022.md) | [62.6](/filings/0001667011-25-000029.md) | [66.8](/filings/0001628280-25-048977.md) | [73.2](/filings/0001628280-26-054464.md) | [84.5](/filings/0001628280-26-034186.md) | [93.3](/filings/0001628280-26-054464.md) |
| Total liabilities | $m | [80.1](/filings/0001667011-23-000030.md) | [87.7](/filings/0001667011-25-000010.md) | [91.8](/filings/0001667011-24-000016.md) | [91.1](/filings/0001667011-24-000026.md) | [95.5](/filings/0001667011-24-000036.md) | [107](/filings/0001628280-26-007726.md) | [103](/filings/0001667011-25-000022.md) | [114](/filings/0001667011-25-000029.md) | [119](/filings/0001628280-25-048977.md) | [130](/filings/0001628280-26-054464.md) | [137](/filings/0001628280-26-034186.md) | [157](/filings/0001628280-26-054464.md) |
| Shareholders' equity | $m | [22.0](/filings/0001667011-24-000036.md) | [15.1](/filings/0001628280-26-007726.md) | [9.5](/filings/0001667011-25-000029.md) | [5.3](/filings/0001628280-25-048977.md) | [2.2](/filings/0001628280-25-048977.md) | [(1.2)](/filings/0001628280-26-054464.md) | [(4.8)](/filings/0001628280-26-054464.md) | [(7.5)](/filings/0001628280-26-054464.md) | [(11.4)](/filings/0001628280-25-048977.md) | [(14.6)](/filings/0001628280-26-054464.md) | [2.6](/filings/0001628280-26-054464.md) | [67.7](/filings/0001628280-26-054464.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,806) d](/filings/0001667011-24-000036.md) | [(2,979) d](/filings/0001667011-25-000010.md) | [477](/filings/0001667011-25-000022.md) | [311 d](/filings/0001667011-25-000029.md) | [1,123 d](/filings/0001628280-25-048977.md) | [(2,631) d](/filings/0001628280-26-007726.md) | [2,860](/filings/0001628280-26-034186.md) | [(2,485) d](/filings/0001628280-26-054464.md) | [3,188 d](/filings/0001628280-25-048977.md) | [3,170 d](/filings/0001628280-26-007726.md) | [(7,062)](/filings/0001628280-26-034186.md) | [9,210 d](/filings/0001628280-26-054464.md) |
| Capital expenditure | $k | [340 d](/filings/0001667011-24-000036.md) | [428 d](/filings/0001667011-25-000010.md) | [196](/filings/0001667011-25-000022.md) | [47.0 d](/filings/0001667011-25-000029.md) | [31.0 d](/filings/0001628280-25-048977.md) | [50.0 d](/filings/0001628280-26-007726.md) | [183](/filings/0001628280-26-034186.md) | [355 d](/filings/0001628280-26-054464.md) | [716 d](/filings/0001628280-25-048977.md) | [134 d](/filings/0001628280-26-007726.md) | [295](/filings/0001628280-26-034186.md) | [595 d](/filings/0001628280-26-054464.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.8](/filings/0001667011-23-000030.md) | [34.6](/filings/0001667011-24-000016.md) | [35.3](/filings/0001667011-24-000026.md) | [36.0](/filings/0001667011-24-000036.md) | [37.7](/filings/0001667011-25-000022.md) | [38.5](/filings/0001667011-25-000029.md) | [39.3](/filings/0001628280-25-048977.md) | [40.9](/filings/0001628280-26-034186.md) | [41.8](/filings/0001628280-26-054464.md) | [42.7](/filings/0001628280-25-048977.md) | [45.5](/filings/0001628280-26-034186.md) | [47.3](/filings/0001628280-26-054464.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,152,102 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054464.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.